Haemonetics (HAE) Q3 2026: Plasma Organic Growth Hits 20% as Margin Expansion Drives Cash Flow Surge
Plasma’s 20% organic growth and expanding gross margins propelled Haemonetics to raise its full-year guidance, even as hospital and interventional technologies lagged. Cash generation rebounded sharply, supporting capital flexibility and targeted investments. FY27 pivots hinge on IVT turnaround and sustaining plasma’s competitive edge.
Summary
- Plasma Leadership Drives Upward Guidance: Share gains and innovation in plasma offset hospital softness, anchoring raised outlook.
- Margin Expansion Fuels Cash Generation: Portfolio transformation and cost discipline deliver robust free cash flow.
- IVT Execution Remains Critical: Interventional turnaround and new product launches set the stage for FY27 recovery.
Business Overview
Haemonetics is a global medical technology company specializing in blood and plasma collection, processing, and management solutions. The company’s revenue streams are anchored in three major segments: Hospital (blood management and interventional technologies), Plasma (collection systems for plasma fractionators), and Blood Center (products for blood banks and collection centers). Revenue is generated through sales of capital equipment, disposables, and related services, with plasma and hospital blood management technologies representing the company’s primary growth engines.
Performance Analysis
Q3 performance was defined by plasma’s outperformance, with organic growth excluding CSL (a major customer) reaching 20% in the quarter and 22% year to date. Plasma’s strength was driven by a “trifecta” of share gains, price annualization from new technology rollouts, and robust collection volumes, with U.S. and international markets both growing double digits. This segment now contributes roughly half of company-wide organic growth, highlighting its outsized influence.
Hospital segment results were mixed: blood management technologies delivered solid 8% growth, but interventional technologies (IVT) declined 12% on softness in esophageal cooling and OEM headwinds. Vascular closure also fell 4%, with management attributing most of the IVT decline to procedural and competitive disruptions. Gross margin expansion continued (up 250 basis points to 60.2% in Q3), aided by product mix, the divestiture of low-margin businesses, and Nexus with Persona adoption. Operating margin reached 26.3% in Q3, with all segments contributing to year-to-date expansion, though hospital softness pressured leverage. Free cash flow conversion was a highlight, exceeding 120% of adjusted net income in Q3 and prompting a guidance raise.
- Plasma Momentum: Organic growth ex-CSL at 20% underpinned by share gains and innovation-based pricing.
- Hospital Mixed: Blood management buoyed results, but IVT and vascular closure underperformed, with IVT down 12%.
- Cash Flow Strength: Free cash flow conversion rebounded to 121% of adjusted net income, restoring capital flexibility.
Portfolio transformation and disciplined cost control have structurally improved profitability, offsetting segment volatility and positioning Haemonetics for continued earnings growth ahead of revenue.
Executive Commentary
"Nexus and TAG delivered outsized growth driven by sustained share gains, innovation-based pricing, and durable end-market demand, demonstrating the strength and resilience of these core products and our increasingly productive operating model."
Chris Simon, Chief Executive Officer
"Cash generation has reemerged as a defining strength of Haemonetics and a core source of strategic flexibility. With our major device build-out complete and a series of company-wide productivity initiatives now largely behind us, the business has returned to the robust cash flow profile that it's historically been known for."
James Derecka, Chief Financial Officer
Strategic Positioning
1. Plasma Platform as Growth Engine
Haemonetics’ plasma business now anchors the company’s growth trajectory, with technology-driven share gains and price realization outpacing end-market growth. The Nexus PCS with Persona, next-gen plasma collection system, has enabled both direct share wins and empowered customers to gain market share, creating a dual growth effect. Management signaled confidence in plasma’s sustainability, pending further customer demand discussions for FY27.
2. Hospital Segment: Blood Management Strength, IVT Turnaround Required
Blood management technologies (BMT) are offsetting interventional weakness, with TAG6S and heparinase neutralization cartridges driving device utilization and account conversions. However, IVT’s 12% decline, largely from esophageal cooling/PFA disruption and OEM realignment, remains a drag. Leadership is betting on MVP XL label expansion and the Percocel Elite launch to restore IVT growth in FY27.
3. Margin Expansion and Portfolio Rationalization
Portfolio transformation—divesting low-margin businesses and prioritizing high-value innovation—has structurally lifted margins. Gross margin expansion was driven by favorable mix, Nexus adoption, and the exit of whole blood and underperforming products. These changes have delivered 770 basis points of margin improvement over four years, underpinning durable earnings leverage.
4. Cash Flow Rebound and Capital Allocation
Free cash flow surged, restoring Haemonetics’ historical cash conversion profile. With major capital projects completed, the company now has flexibility for organic investment, debt reduction, and opportunistic buybacks. The $61 million VivaSure acquisition, focused on large-bore vascular closure, is a measured bet on future IVT leadership.
5. Commercial Execution and Competitive Response
Management is aggressively rebuilding IVT sales execution, citing a revitalized field force and improved account tracking. Over 60% of the team is new to their territories, supporting optimism for win-back momentum in key accounts. Commercial initiatives are designed to stabilize share and prepare for new product launches in FY27.
Key Considerations
This quarter affirmed Haemonetics’ ability to leverage plasma strength and margin expansion to counterbalance hospital volatility. The company’s strategic context is defined by:
Key Considerations:
- Plasma Durability: Sustained double-digit collection growth and share gains suggest plasma’s outperformance can persist, but cyclical risks remain.
- IVT Recovery Trajectory: Execution on MVP XL and Percocel Elite launches is critical to restoring hospital segment growth in FY27.
- Margin Sustainability: Gross margin gains from portfolio pruning and mix improvement have proven durable, but future expansion will likely be incremental.
- Capital Flexibility: Robust cash generation enables balanced capital deployment, with organic growth and tactical M&A prioritized over further cost out.
- Competitive Dynamics: Aggressive commercial efforts and new field leadership are essential to regaining share in vascular closure and interventional markets.
Risks
Key risks center on plasma market cyclicality, as collection volumes and pricing can ebb with immunoglobulin demand and inventory cycles. IVT’s turnaround is not guaranteed, with competitive pressure and procedural shifts creating execution risk. Regulatory or reimbursement changes, especially in plasma or vascular closure, could disrupt growth. Management’s guidance prudently excludes uncontrollable volume upside, but also reflects hospital stabilization assumptions that may be optimistic if execution falters.
Forward Outlook
For Q4 2026, Haemonetics guided to:
- Company-wide reported revenue decline of 1% to 3%, improved from prior guidance.
- Organic revenue growth ex-CSL of 8% to 10%, raised at the midpoint.
- Adjusted operating margin of 26% to 27% for the full year.
- Free cash flow of $200 million to $220 million, up from $170 million to $210 million previously.
Management highlighted several factors that will shape Q4 and FY27:
- Plasma’s continued share gains and innovation-driven pricing are expected to anchor growth.
- IVT stabilization and new product launches are essential for hospital segment recovery.
Takeaways
Haemonetics’ Q3 confirms plasma as the company’s primary value driver, with margin expansion and cash flow conversion restoring strategic flexibility. Hospital segment’s mixed results keep the spotlight on IVT execution, while management’s disciplined capital allocation and portfolio focus have created a higher-quality earnings base.
- Plasma Outperformance: Share gains and innovation have reset the growth baseline, but future sustainability depends on continued end-market demand and competitive moat maintenance.
- IVT and Hospital Execution: The path to FY27 growth hinges on successful launches and commercial execution in vascular closure and interventional technologies.
- Margin and Cash Flow Leverage: Portfolio transformation has yielded durable margin gains, supporting ongoing investment and shareholder returns.
Conclusion
Haemonetics delivered a quarter marked by plasma-driven growth, robust margin expansion, and a return to strong cash generation. While hospital and IVT headwinds persist, the company’s strategic focus and financial discipline have positioned it for a potential inflection in FY27, provided execution on new product launches and commercial initiatives materializes.
Industry Read-Through
Haemonetics’ plasma momentum and margin gains signal ongoing strength in global plasma collection and immunoglobulin demand, with innovation and share shifts driving outperformance for technology leaders. The hospital segment’s IVT volatility and procedural disruption mirror broader medtech challenges from shifting care sites and new therapeutic modalities (e.g., PFA adoption). Portfolio pruning and focus on high-value innovation are increasingly prerequisites for durable margin expansion in medtech. Competitors and peers should note the importance of execution in commercial rebuilds and the leverage created by disciplined capital allocation and cash flow restoration.